[en] OBJECTIVE: To evaluate the economic impact of introducing the soluble fms-like tyrosine kinase (sFlt-1) to placental growth factor (PlGF) ratio test into clinical practice in Belgium for the prediction of preeclampsia (PE). STUDY DESIGN: We developed a one-year time-horizon decision tree model to evaluate the short-term costs associated with the introduction of the sFlt-1/PlGF test for guiding the management of women with suspected PE from the Belgian public healthcare payers' perspective. The model estimated the costs associated with the diagnosis and management of PE in pregnant women managed in either a test scenario, in which the sFlt-1/PlGF test is used in addition to current clinical practice, or a no test scenario, in which clinical decisions are based on current practice alone. Test characteristics were derived from PROGNOSIS, a non-interventional study in women presenting with clinical suspicion of PE. Unit costs were obtained from Belgian-specific sources. The main model outcome was the total cost per patient. RESULTS: Introduction of the sFlt-1/PlGF ratio test is expected to result in a cost saving of €712 per patient compared with the no test scenario. These savings are generated mainly due to a reduction in unnecessary hospitalizations. CONCLUSIONS: The sFlt-1/PlGF test is projected to result in substantial cost savings for the Belgian public healthcare payers through reduction of unnecessary hospitalization of women with clinical suspicion of PE that ultimately do not develop the condition. The test also has the potential to ensure that women at high risk of developing PE are identified and appropriately managed.
Disciplines :
Reproductive medicine (gynecology, andrology, obstetrics)
Author, co-author :
Chantraine, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gynécologie-obstétrique (CHR) ; Department of Obstetrics and Gynecology, Centre Hospitalier Universitaire de
Van Calsteren, Kristel; Department of Obstetrics and Gynaecology, University Hospitals, KULeuven, Leuven,
Devlieger, Roland; Department of Obstetrics and Gynaecology, University Hospitals, KULeuven, Leuven,
Gruson, Damien; Department of Laboratory Medicine, Division of Clinical Biochemistry, Cliniques
Keirsbilck, Joachim Van; Department of Obstetrics and Gynaecology, St Jan's Hospital, Bruges, Belgium.
Stepan, H., Kuse-Fohl, S., Klockenbusch, W., Rath, W., Schauf, B., Walther, T., et al. Diagnosis and treatment of hypertensive pregnancy disorders. Guideline of DGGG (S1-level, AWMF registry no. 015/018, December 2013). Geburtshilfe Frauenheilkd 75 (2015), 900–914, 10.1055/s-0035-1557924.
Duley, L., The global impact of pre-eclampsia and eclampsia. Semin. Perinatol. 33:3 (2009), 130–137, 10.1053/j.semperi.2009.02.010.
Brown, M.A., Magee, L.A., Kenny, L.C., Karumanchi, S.A., McCarthy, F.P., Saito, S., Hall, D.R., Warren, C.E., Adoyi, G., Ishaku, S., Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension 72:1 (2018), 24–43, 10.1161/HYPERTENSIONAHA.117.10803.
Milne, F., Redman, C., Walker, J., Baker, P., Black, R., Blincowe, J., Cooper, C., Fletcher, G., Jokinen, M., Moran, P.A., Nelson-Piercy, C., Robson, S., Shennan, A., Tuffnell, A., Waugh, J., Assessing the onset of pre-eclampsia in the hospital day unit: summary of the pre-eclampsia guideline (PRECOG II). BMJ, 339, 2009, b3129, 10.1136/bmj.b3129.
Young, B.C., Karumanchi, S.A., Toward a better diagnosis for preeclampsia. Clin. Chem. 62 (2016), 913–915, 10.1373/clinchem.2016.254920.
Rana, S., Lemoine, E., Granger, J.P., Karumanchi, S.A., Preeclampsia: pathophysiology, challenges, and perspectives. Circ. Res. 124:7 (2019), 1094–1112, 10.1161/CIRCRESAHA.118.313276.
Stevens, W., Shih, T., Incerti, D., Ton, T.G.N., Lee, H.C., Peneva, D., Macones, G.A., Sibai, B.M., Jena, A.B., Short-term costs of preeclampsia to the United States health care system. Am. J. Obstet. Gynecol. 217:3 (2017), 237–248.e16, 10.1016/j.ajog.2017.04.032.
Liu, A., Wen, S.W., Bottomley, J., Walker, M.C., Smith, G., Utilization of health care services of pregnant women complicated by preeclampsia in Ontario. Hypertens. Pregn. 28:1 (2009), 76–84, 10.1080/10641950802366252.
Hund, M., Allegranza, D., Schoedl, M., Dilba, P., Verhagen-Kamerbeek, W., Stepan, H., Multicenter prospective clinical study to evaluate the prediction of short-term outcome in pregnant women with suspected preeclampsia (PROGNOSIS): study protocol. BMC Pregn. Childbirth, 14, 2014, 324, 10.1186/1471-2393-14-324.
Levine, R.J., Lam, C., Qian, C., Yu, K.F., Maynard, S.E., Sachs, B.P., Sibai, B.M., Epstein, F.H., Romero, R., Thadhani, R., Karumanchi, S.A., Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med. 355:10 (2006), 992–1005, 10.1056/NEJMoa055352.
Verlohren, S., Galindo, A., Schlembach, D., Zeisler, H., Herraiz, I., Moertl, M.G., Pape, J., Dudenhausen, J.W., Denk, B., Stepan, H., An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am. J. Obstet. Gynecol. 202:2 (2010), 161.e1–161.e11, 10.1016/j.ajog.2009.09.016.
Schiettecatte, J., Russcher, H., Anckaert, E., Mees, M., Leeser, B., Tirelli, A.S., Fiedler, G.M., Luthe, H., Denk, B., Smitz, J., Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia. Clin. Biochem. 43:9 (2010), 768–770, 10.1016/j.clinbiochem.2010.02.010.
Verlohren, S., Herraiz, I., Lapaire, O., Schlembach, D., Zeisler, H., Calda, P., Sabria, J., Markfeld-Erol, F., Galindo, A., Schoofs, K., Denk, B., Stepan, H., New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension 63:2 (2014), 346–352, 10.1161/HYPERTENSIONAHA.113.01787.
Sunderji, S., Gaziano, E., Wothe, D., Rogers, L.C., Sibai, B., Karumanchi, S.A., Hodges-Savola, C., Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am. J. Obstet. Gynecol. 202:1 (2010), 40.e1–40.e7, 10.1016/j.ajog.2009.07.025.
Zeisler, H., Llurba, E., Chantraine, F., Vatish, M., Staff, A.C., Sennström, M., Olovsson, M., Brennecke, S.P., Stepan, H., Allegranza, D., Dilba, P., Schoedl, M., Hund, M., Verlohren, S., Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N. Engl. J. Med. 374:1 (2016), 13–22, 10.1056/NEJMoa1414838.
European Commission, Defining ‘value’ in ‘value-based healthcare’: report of the expert panel on effective ways of investing in health (EXPH). https://ec.europa.eu/health/sites/health/files/expert_panel/docs/024_defining-value-vbhc_en.pdf, 2019 (accessed 2 July 2021).
Vatish, M., Strunz‐McKendry, T., Hund, M., Allegranza, D., Wolf, C., Smare, C., sFlt-1/PlGF ratio test for pre-eclampsia: an economic assessment for the UK. Ultrasound Obstet. Gynecol. 48:6 (2016), 765–771, 10.1002/uog.2016.48.issue-610.1002/uog.15997.
Frusca, T., Gervasi, M.-T., Paolini, D., Dionisi, M., Ferre, F., Cetin, I., Budget impact analysis of sFlt-1/PlGF ratio as prediction test in Italian women with suspected preeclampsia. J. Matern. Fetal Neonatal Med. 30:18 (2017), 2166–2173, 10.1080/14767058.2016.1242122.
Schlembach, D., Hund, M., Schroer, A., Wolf, C., Economic assessment of the use of the sFlt-1/PlGF ratio test to predict preeclampsia in Germany. BMC Health Serv. Res., 18, 2018, 603, 10.1186/s12913-018-3406-1.
Hodel, M., Blank, P.R., Marty, P., Lapaire, O., sFlt-1/PlGF ratio as a predictive marker in women with suspected preeclampsia: an economic evaluation from a Swiss perspective. Dis. Mark. 2019 (2019), 1–10, 10.1155/2019/4096847.
Campos, A., Machado, A., Martins, H., Sao Jose Pais, M., Ersek, K., Lopes, N., sFlt-1/PlGF ratio for the predictive diagnosis of preeclampsia: budget impact analysis from the public healthcare perspective in Portugal. Acta Obstet. Ginecol. Port. 13 (2019), 82–90.
Figueira, S.F., Wolf, C., D'Innocenzo, M., de Carvalho, J.P.V., Barbosa, M.G., Zlotnik, E., Cordioli, E., Economic evaluation of sFlt-1/PlGF ratio test in pre-eclampsia prediction and diagnosis in two Brazilian hospitals. Pregn. Hypertens. 13 (2018), 30–36, 10.1016/j.preghy.2018.04.014.
Zeisler, H., Llurba, E., Chantraine, F.J., Vatish, M., Staff, A.C., Sennström, M., Olovsson, M., Brennecke, S.P., Stepan, H., Allegranza, D., Schoedl, M., Grill, S., Hund, M., Verlohren, S., Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting. Ultrasound Obstet. Gynecol. 53:3 (2019), 367–375, 10.1002/uog.19178.
Stepan, H., Herraiz, I., Schlembach, D., Verlohren, S., Brennecke, S., Chantraine, F., Klein, E., Lapaire, O., Llurba, E., Ramoni, A., Vatish, M., Wertaschnigg, D., Galindo, A., Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. Ultrasound Obstet. Gynecol. 45:3 (2015), 241–246, 10.1002/uog.14799.
National Collaborating Centre for Women's and Children's Health (UK), Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy. NICE Clinical Guidelines, No. 107. https://www.ncbi.nlm.nih.gov/books/NBK62652/, 2010 (accessed 2 July 2021).
NICE, PlGF-based testing to help diagnose suspected pre-eclampsia (Triage PlGF test, Elecsys immunoassay sFlt-1/PlGF ratio, DELFIA Xpress PlGF 1-2-3 test, and BRAHMS sFlt-1 Kryptor/BRAHMS PlGF plus Kryptor PE ratio): NICE diagnostics guidance [DG23]. https://www.nice.org.uk/guidance/dg23/chapter/1-Recommendations, 2016 (accessed 2 July 2021).
Cleemput I, Neyt M, Van de Sande S, Thiry N, Belgian guidelines for economic evaluations and budget impact analyses: second edition. Health Technology Assessment (HTA). Brussels: Belgian Health Care Knowledge Centre (KCE). 2012. KCE Report 183C. D/2012/10.273/54.
RIZIV, NomenSoft. https://ondpanon.riziv.fgov.be/Nomen/nl/search, 2020 (accessed 25 November 2020).
Technische Cel. https://tct.fgov.be/webetct/etct-web/, 2020 (accessed 25 November 2020).
BFCI, Commended Medicines Directory. https://www.bcfi.be/nl/chapters/2?frag=653&trade_family=27318, 2021 (accessed 05 January 2021).
Statbel, Consumer price index, by base year, COICOP nomenclature, by year and month. https://bestat.statbel.fgov.be/bestat/crosstable.xhtml?view=ea07572b-7fc4-40f7-af62-d20b70941e86, 2020 (accessed 25 November 2020).
St John, A., The pursuit of value in laboratory medicine - progress and challenges. Clin. Biochem. Rev. 41 (2020), 3–11, 10.33176/AACB-19-00035.
Hallworth, M.J., Epner, P.L., Ebert, C., Fantz, C.R., Faye, S.A., Higgins, T.N., Kilpatrick, E.S., Li, W., Rana, S.V., Vanstapel, F., Current evidence and future perspectives on the effective practice of patient-centered laboratory medicine. Clin. Chem. 61:4 (2015), 589–599, 10.1373/clinchem.2014.232629.
Statbel, Births and fertility 2018. https://statbel.fgov.be/en/themes/population/births-and-fertility#figures, 2018 (accessed 2 July 2021).
Hadker, N., Garg, S., Costanzo, C., van der Helm, W., Creeden, J., Are there financial savings associated with supplementing current diagnostic practice for preeclampsia with a novel test? Learnings from a modeling analysis from a German payer perspective. Hypertens. Pregn. 32:2 (2013), 105–119, 10.3109/10641955.2011.638958.
Hadker, N., Garg, S., Costanzo, C., Miller, J.D., Foster, T., van der Helm, W., Creeden, J., Financial impact of a novel pre-eclampsia diagnostic test versus standard practice: a decision-analytic modeling analysis from a UK healthcare payer perspective. J. Med. Econ. 13:4 (2010), 728–737, 10.3111/13696998.2010.535285.
Schnettler, W.T., Dukhovny, D., Wenger, J., Salahuddin, S., Ralston, S.J., Rana, S., Cost and resource implications with serum angiogenic factor estimation in the triage of preeclampsia. BJOG 120:10 (2013), 1224–1232, 10.1111/1471-0528.12259.
Duckworth, S., Chappell, L.C., Seed, P.T., Mackillop, L., Shennan, A.H., Hunter, R., Croy, A., Placental growth factor (PlGF) in women with suspected pre-eclampsia prior to 35 weeks' gestation: a budget impact analysis. PLoS ONE, 11(10), 2016, e0164276, 10.1371/journal.pone.0164276.
Klein, E., Schlembach, D., Ramoni, A., Langer, E., Bahlmann, F., Grill, S., Schaffenrath, H., van der Does, R., Messinger, D., Verhagen-Kamerbeek, W.D.J., Reim, M., Hund, M., Stepan, H., Zenclussen, A.C., Influence of the sFlt-1/PlGF ratio on clinical decision-making in women with suspected preeclampsia. PLoS ONE, 11(5), 2016, e0156013, 10.1371/journal.pone.0156013.
Hund, M., Verhagen-Kamerbeek, W., Reim, M., Messinger, D., van der Does, R., Stepan, H., Influence of the sFlt-1/PlGF ratio on clinical decision-making in women with suspected preeclampsia–the PreOS study protocol. Hypertens. Pregn. 34:1 (2015), 102–115, 10.3109/10641955.2014.982331.
Stepan, H., Hund, M., Dilba, P., Sillman, J., Schlembach, D., Elecsys® and Kryptor immunoassays for the measurement of sFlt-1 and PlGF to aid preeclampsia diagnosis: are they comparable?. Clin. Chem. Lab. Med. 57 (2019), 1339–1348, 10.1515/cclm-2018-1228.
Roberge, S., Villa, P., Nicolaides, K., Giguère, Y., Vainio, M., Bakthi, A., Ebrashy, A., Bujold, E., Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn. Ther. 31:3 (2012), 141–146, 10.1159/000336662.
O'Gorman, N., Wright, D., Syngelaki, A., Akolekar, R., Wright, A., Poon, L.C., Nicolaides, K.H., Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11–13 weeks gestation. Am. J. Obstet. Gynecol. 214:1 (2016), 103.e1–103.e12, 10.1016/j.ajog.2015.08.034.
Dubon Garcia, A., Devlieger, R., Redekop, K., Vandeweyer, K., Verlohren, S., Poon, L.C., Cost-utility of a new first-trimester screening strategy versus the standard of care for nulliparous women to prevent pre-term pre-eclampsia in Belgium. Pregn. Hypertens. 25 (2021), 219–224, 10.1016/j.preghy.2021.06.012.
